Ardena Group launches Life Science Ingredients arm
The news business will manufacture chemical ingredients that can be used in the development of drug products, and in the healthcare and cosmetics industries.
CDMO Ardena has launched Ardena LSI, a new arm of its business dedicated to the sale of chemical ingredients and intermediates for the life science industry.
Ardena LSI will manufacture chemical ingredients for the development of drug products in the Group’s European GMP certified plants, including BDDE 98% GMP (1,4-Butanediol diglycidyl ether) and EDC-HCl Ultra Pure.
The ingredients can be used by pharmaceutical manufacturers in the development of drug products, and for application in healthcare and cosmetics products such as dermal fillers
Harry Christiaens, CEO of Ardena, said: “The healthcare and cosmetic industry require a high and consistent quality of chemical ingredients to enable the manufacture of safe and reliable products.
“We have built up extensive experience as a CDMO in the area of chemical synthesis and through Ardena LSI we are now harnessing that experience to manufacture high-quality chemical ingredients that are essential for pharmaceutical manufacturers in European markets.
“Customers need suppliers that truly understand the chemistry behind drug development, and we will work closely with them to understand their specific requirements and provide the ingredient quality and volumes that they need according to GMP guidelines.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.